0FIW Stock Chart & Stats
kr28.70
kr0.55(1.95%)
At close: 4:00 PM EDT
kr28.70
kr0.55(1.95%)
Day’s Range― - ―
52-Week Rangekr25.90 - kr36.40
Previous CloseN/A
Volume150.00
Average Volume (3M)2.47K
Market Cap
kr12.09B
Enterprise Valuekr14.29K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)18.9
Beta0.38
Next Earnings
Oct 20, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.44
Shares Outstanding428,000,000
10 Day Avg. Volume678
30 Day Avg. Volume2,472
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr40.00Price Target Upside39.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Embla Medical hf News
0FIW FAQ
What was Embla Medical hf’s price range in the past 12 months?
Embla Medical hf lowest share price was kr25.90 and its highest was kr36.40 in the past 12 months.
What is Embla Medical hf’s market cap?
Embla Medical hf’s market cap is kr12.09B.
When is Embla Medical hf’s upcoming earnings report date?
Embla Medical hf’s upcoming earnings report date is Oct 20, 2026 which is in 74 days.
How were Embla Medical hf’s earnings last quarter?
Embla Medical hf released its earnings results on Jul 21, 2026. The company reported kr0.441 earnings per share for the quarter, beating the consensus estimate of kr0.363 by kr0.078.
Is Embla Medical hf overvalued?
According to Wall Street analysts Embla Medical hf’s price is currently Undervalued.
Does Embla Medical hf pay dividends?
Embla Medical hf does not currently pay dividends.
What is Embla Medical hf’s EPS estimate?
Embla Medical hf’s EPS estimate is 0.43.
How many shares outstanding does Embla Medical hf have?
Embla Medical hf has 428,000,000 shares outstanding.
What happened to Embla Medical hf’s price movement after its last earnings report?
Embla Medical hf reported an EPS of kr0.441 in its last earnings report, beating expectations of kr0.363. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Embla Medical hf?
Currently, no hedge funds are holding shares in GB:0FIW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Embla Medical hf
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides osteoarthritis solutions that are designed to reduce pain and improve mobility for people living with osteoarthritis; and injury solutions for people recovering from fractures, ligament injuries, or need post-operative treatment. This segment also offers Unloader One, a range knee braces that relieve pain from knee osteoarthritis; and Unloader Hip, which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip. The Patient Care segment provides prosthetics for people with lower and upper limb loss or limb difference; and orthotics for neurological, gait, and musculoskeletal conditions. The company serves orthopedic and prosthetic clinics, hospitals, and surgery centers. It sells its products through its direct sales networks and distributors. The company was formerly known as Össur hf. and changed its name to Embla Medical hf. in April 2024. Embla Medical hf. was incorporated in 1971 and is headquartered in Reykjavik, Iceland. Embla Medical hf. is a subsidiary of William Demant Invest A/S.
0FIW Company Deck
0FIW Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated multiple clear positives: solid organic growth (6% FY), strong cash generation ($100M FCF, 11% of sales), product and reimbursement milestones, strategic acquisition (Streifeneder) and continued margin targets with guidance for 2026. Headwinds include temporary disruption in Patient Care from integration/rebranding initiatives, softness in Bracing, FX and tariff pressures and flat performance in the Americas. Management expects Patient Care to recover gradually and provided a reasonably constructive 2026 outlook (5%–8% organic growth, 20%–22% EBITDA margin). Overall, the operational and financial progress, cash strength and strategic milestones outweigh near-term execution and external headwinds.View all GB:0FIW earnings summaries0FIW Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
kr40.00
▲(39.37% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Embla Medical hf
―
Smith & Nephew Snats
―
Zimmer Biomet Holdings
―
Stryker
―
Medtronic
―
Boston Scientific
―
Globus Medical
―








